A

AbbVie

Global biopharmaceutical company developing medicines

Field Reimbursement Manager - Parkinson’s

Full-TimePosted on 10/23/2026
$139k - $250.5k/yr+ Long-term incentive programs
Mid
Bachelor's
Omaha, NE, USA+1 moreMore locations: Minneapolis, MN, USA
In PersonField-based role calling on HCP offices in assigned territories; candidates should live within a reasonable distance of Minneapolis or Omaha.
Solution EngineeringImplementation & Technical Account Management

About the job

Requirements
  • At least 3 years of experience in Neuroscience with experience in Managed Health Care, Payer Account Management, and/or Access and Reimbursement.
  • Thorough understanding of the technical payer policy processes, systems, and requirements for coverage, coding, and payment for specialty medicines.
  • Demonstrated understanding of the rules, regulations, and risks associated with provision of reimbursement support services.
  • Strong understanding and ability to communicate technical elements of coding and billing requirements at the national and regional level across all settings of care.
  • Comprehensive understanding of Parts A, B, C, and D of Medicare and associated reimbursement dynamics.
  • Strong understanding of drug acquisition and dispensing in the Neuroscience space, including specialty pharmacies, specialty distributors, and white-bagging.
  • Strong understanding of access and reimbursement support service centers and how to interact with them compliantly.
  • Excellent territory and account management skills.
  • Bachelor’s degree and a valid driver’s license.
  • Must satisfy applicable health care industry representative credentialing requirements to gain and maintain entry into facilities and organizations in the assigned territory, and be in good standing and/or eligible to obtain these credentials. These requirements may include background checks, drug screens, proof of immunization or vaccination, fingerprinting, and specific licenses required by individual states or cities; the candidate is responsible for meeting these requirements and any associated liability.
Responsibilities
  • Educate health care professionals on patient support programs, including access and reimbursement support tools and services.
  • Educate health care professionals on product-specific acquisition and access options, such as specialty pharmacy networks and specialty distribution.
  • Educate health care professionals on resources available to address access issues.
  • Provide local expertise regarding national and regional payer policies to educate providers on payer issues, coding changes, and appropriate claims submission processes.
  • Liaise with AbbVie’s Access and Reimbursement support center to update health care professionals on prescription status and program eligibility.
  • Report payer trends for approved products to Patient Services and MHC account management teams.
  • Establish and maintain relationships with appropriate providers within the territory.
  • Remain current on key managed care, reimbursement, and policy activities.
  • Call directly on health care professional offices in an assigned geography to answer patient access and reimbursement questions in support of Duopa, Vyalev, and Juvmo.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.